Q-omics provides the consensus-scored SNORD88A profile across patient tissues and cancer cell-line models. SNORD88A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SNORD88A is differentially expressed in 17, with the highest sampling consensus in COAD. Additionally, SNORD88A RNA expression shows 12,150 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight UVM, COAD, and LUAD as cancer lineages where SNORD88A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD88A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD88A survival associations across molecular data types. SNORD88A RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD88A RNA expression–survival associations across cancer types. High SNORD88A expression shows unfavorable associations in UVM, LUAD, MESO, THYM and PRAD, but favorable associations in STAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SNORD88A RNA expression.
This table summarizes SNORD88A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD88A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD88A shows higher tumor expression in COAD, KICH, STAD, KIRC, LUSC and READ. The COAD box plot shows higher SNORD88A RNA expression in tumor versus normal tissue (log2 FC = +1.154, t-test p < 0.001).
This table shows molecular features associated with SNORD88A in patient tissues and cancer cell lines. In patient samples, SNORD88A shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
